Similar articles for PMID: 20519186

Year	Number of Results
1972	1
1999	1
2006	2
2007	15
2008	19
2009	16
2010	14
2011	26
2012	28
2013	36
2014	34
2015	27
2016	18
2017	7
2018	5
2019	4
2020	4
2022	4
2024	0

1

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

Abel T, Fehér J. Abel T, et al. Orv Hetil. 2010 Jun 20;151(25):1012-6. doi: 10.1556/OH.2010.28910. Orv Hetil. 2010. PMID: 20519186 Review. Hungarian.

2

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR. Bailey CJ, et al. Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Expert Opin Investig Drugs. 2010. PMID: 20629618 Review.

3

Sitagliptin: a review.

Subbarayan S, Kipnes M. Subbarayan S, et al. Expert Opin Pharmacother. 2011 Jul;12(10):1613-22. doi: 10.1517/14656566.2011.580738. Expert Opin Pharmacother. 2011. PMID: 21651449 Review.

4

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.

5

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ. Scheen AJ. Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Postgrad Med. 2013. PMID: 23748503 Free article. Review.

6

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ. Alba M, et al. Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514. Curr Med Res Opin. 2009. PMID: 19691426 Clinical Trial.

7

Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.

[No authors listed] [No authors listed] Prescrire Int. 2009 Jun;18(101):115. Prescrire Int. 2009. PMID: 19637427 No abstract available.

8

DPP-4 inhibitors in clinical practice.

Palalau AI, Tahrani AA, Piya MK, Barnett AH. Palalau AI, et al. Postgrad Med. 2009 Nov;121(6):70-100. doi: 10.3810/pgm.2009.11.2079. Postgrad Med. 2009. PMID: 19940419 Review.

9

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

Herman GA, Stein PP, Thornberry NA, Wagner JA. Herman GA, et al. Clin Pharmacol Ther. 2007 May;81(5):761-7. doi: 10.1038/sj.clpt.6100167. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392725 Review.

10

[Sitagliptin].

Taéron C. Taéron C. Rev Infirm. 2008 Oct;(144):46-8. Rev Infirm. 2008. PMID: 19009789 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

247 results

Results by year